Absence of Glucagon and Insulin Action Reveals a Role for the GLP-1 Receptor in Endogenous Glucose Production
The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
The absence of insulin results in oscillating hyperglycemia and ketoacidosis in type 1 diabetes. Remarkably, mice genetically deficient in the glucagon receptor (Gcgr) are refractory to the pathophysiological symptoms of insulin deficiency, and therefore, studies interrogating this unique model may uncover metabolic regulatory mechanisms that are independent of insulin. A significant feature of Gcgr-null mice is the high circulating concentrations of GLP-1. Hence, the objective of this report was to investigate potential noninsulinotropic roles of GLP-1 in mice where GCGR signaling is inactivated. For these studies, pancreatic β-cells were chemically destroyed by streptozotocin (STZ) in Gcgr−/−:Glp-1r−/− mice and in Glp-1r−/− animals that were subsequently treated with a high-affinity GCGR antagonist antibody that recapitulates the physiological state of Gcgr ablation. Loss of GLP-1 action substantially worsened nonfasting glucose concentrations and glucose tolerance in mice deficient in, and undergoing pharmacological inhibition of, the GCGR. Further, lack of the Glp-1r in STZ-treated Gcgr−/− mice elevated rates of endogenous glucose production, likely accounting for the differences in glucose homeostasis. These results support the emerging hypothesis that non–β-cell actions of GLP-1 analogs may improve metabolic control in patients with insulinopenic diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 reduces hepatic glucose production, partly by inhibiting the expression and activity of key gluconeogenic enzymes.189–191”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [190]
Citations
Cites
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 5×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialDiabetes mellitus : a fundamental and clinical text
LeRoith, D., Taylor, S. I., & Olefsky, J. M. (2004) · Cited by 699
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680 · cited 4×
“Use of the Gcgr, Glp-1r, and Gcgr:Glp-1r genetic models here builds on previous work in Gcgr mice showing that administration of the GLP-1R peptide antagonist, exendin-4(9-39), worsens glucose tolerance in these animals (19).”
BackgroundMethodResultInfluentialGlucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670 · cited 5×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialThe essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599 · cited 5×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialGlucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472 · cited 5×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialEleazu, C. O., Eleazu, K. C., Chukwuma, S., & Essien, U. N. (2013) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-12-60 · Cited by 459 · cited 5×
“Studies have demonstrated that Gcgr mice administered the diabetogenic chemical agent streptozotocin (STZ), a cytotoxic glucose analog that induces necrotic destruction of pancreatic b-cells (15), are resistant to STZ-induced hyperglycemia (14).”
BackgroundMethodResultInfluentialGerich, J. E., Lorenzi, M., Bier, D. M., Schneider, V., Tsalikian, E., Karam, J. H., & Forsham, P. H. (1975) · New England Journal of Medicine · doi:10.1056/nejm197505082921901 · Cited by 354
Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327 · cited 8×
“To cause maximal b-cell loss, Unger and colleagues (16) established a high-dose STZ treatment regimen that resulted in nearly complete b-cell destruction in Gcgr mice.”
BackgroundMethodResultInfluentialHansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309 · cited 1×
“Compared with reports characterizing single deletion of the Glp-1r on the C57BL/6 genetic background using various recombination approaches (24,40,41), our studies reveal the physiological consequences of Glp-1r ablation are more pronounced in an insulinopenic state when combined on a background of Gcgr deficiency or…”
MethodInsulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303
Wilson-Pérez, H. E., Chambers, A. P., Ryan, K. K., Li, B., Sandoval, D. A., Stoffers, D., Drucker, D. J., Pérez-Tilve, D., & Seeley, R. J. (2013) · Diabetes · doi:10.2337/db12-1498 · Cited by 291
Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system
Xu, E., Kumar, M., Zhang, Y., Ju, W., Obata, T., Zhang, N., Liu, S., Wendt, A., Deng, S., Ebina, Y., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2005.11.015 · Cited by 283
Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., et al. (2013) · Diabetes · doi:10.2337/db12-1116 · Cited by 245
The Banting Memorial Lecture 1975: Diabetes and the Alpha Cell
Unger, R. H. (1976) · Diabetes · doi:10.2337/diab.25.2.136 · Cited by 234
Conarello, S. L., Jiang, G., Mu, J., Li, Z., Woods, J., Zycband, E., Ronan, J., Liu, F., Roy, R. S., Zhu, L., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0481-3 · Cited by 224 · cited 8×
“This discovery is provocative and has many potential implications; however, the STZ treatment failed to abolish plasma insulin concentrations and staining for insulin-positive cells in the pancreata of STZ-treated Gcgr animals (14).”
BackgroundMethodResultInfluentialSloop, K. W., Cao, J. X.-C., Siesky, A. M., Zhang, H. Y., Bodenmiller, D. M., Cox, A. L., Jacobs, S. J., Moyers, J. S., Owens, R. A., Showalter, A. D., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420911 · Cited by 219
Self-citationEffect of glucagon on glucose production during insulin deficiency in the dog.
Cherrington, A. D., Lacy, W. W., & Chiasson, J. L. (1978) · Journal of Clinical Investigation · doi:10.1172/jci109174 · Cited by 213 · cited 5×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialLiver-Specific Disruption of the Murine Glucagon Receptor Produces α-Cell Hyperplasia
Longuet, C., Robledo, A. M., Dean, E. D., Dai, C., Ali, S., McGuinness, I., de Chavez, V., Vuguin, P. M., Charron, M. J., Powers, A. C., et al. (2013) · Diabetes · doi:10.2337/db11-1605 · Cited by 206
Prigeon, R. L., Quddusi, S., Paty, B., & D'Alessio, D. A. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00024.2003 · Cited by 199 · cited 1×
“These results agree with data showing GLP-1 infusion in fasted humans decreases EGP (42) and with studies in Glp-1r mice displaying impaired suppression of EGP and liver glycogen accumulation during hyperinsulinemiceuglycemic clamp experiments (32).”
ResultDiabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome
Umpierrez, G. E., Murphy, M. B., & Kitabchi, A. E. (2002) · Diabetes Spectrum · doi:10.2337/diaspect.15.1.28 · Cited by 197
Hyperglucagonemia and Its Suppression: Importance in the Metabolic Control of Diabetes
Raskin, P., & Unger, R. H. (1978) · New England Journal of Medicine · doi:10.1056/nejm197808312990901 · Cited by 196 · cited 1×
“The effect of excess glucagon is significant because of the broad stimulatory actions glucagon has on catabolic processes in the liver and the hyperglucagonemia that is present in poorly controlled diabetes (8,9).”
BackgroundBanarer, S., McGregor, V. P., & Cryer, P. E. (2002) · Diabetes · doi:10.2337/diabetes.51.4.958 · Cited by 194
Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM
Dinneen, S., Alzaid, A., Turk, D., & Rizza, R. (1995) · Diabetologia · doi:10.1007/bf00400639 · Cited by 190 · cited 5×
“The effect of excess glucagon is significant because of the broad stimulatory actions glucagon has on catabolic processes in the liver and the hyperglucagonemia that is present in poorly controlled diabetes (8,9).”
BackgroundMethodResultInfluentialPederson, R. A., Satkunarajah, M., McIntosh, C. H., Scrocchi, L. A., Flamez, D., Schuit, F., Drucker, D. J., & Wheeler, M. B. (1998) · Diabetes · doi:10.2337/diabetes.47.7.1046 · Cited by 167
Kielgast, U., Krarup, T., Holst, J. J., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-0096 · Cited by 165
Glycemic Control in Mice with Targeted Disruption of the Glucagon Receptor Gene
Parker, J. C., Andrews, K. M., Allen, M. R., Stock, J. L., & McNeish, J. D. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6265 · Cited by 162 · cited 7×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialMetabolic manifestations of insulin deficiency do not occur without glucagon action
Lee, Y., Berglund, E. D., Wang, M.-Y., Fu, X., Yu, X., Charron, M. J., Burgess, S. C., & Unger, R. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205983109 · Cited by 151 · cited 6×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialPostprandial Suppression of Glucagon Secretion Depends on Intact Pulsatile Insulin Secretion
Meier, J. J., Kjems, L. L., Veldhuis, J. D., Lefèbvre, P., & Butler, P. C. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-1449 · Cited by 144
Liraglutide as additional treatment for type 1 diabetes
Varanasi, A., Bellini, N., Rawal, D., Vora, M., Makdissi, A., Dhindsa, S., Chaudhuri, A., & Dandona, P. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0330 · Cited by 129
Ayala, J. E., Bracy, D. P., James, F. D., Julien, B. M., Wasserman, D. H., & Drucker, D. J. (2009) · Endocrinology · doi:10.1210/en.2008-0945 · Cited by 114 · cited 5×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialHope, K. M., Tran, P. O. T., Zhou, H., Oseid, E., Leroy, E., & Robertson, R. P. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1488 · Cited by 112
Gu, W., Yan, H., Winters, K. A., Komorowski, R., Vonderfecht, S. L., Atangan, L. I., Sivits, G. N., Hill, D., Yang, J., Bi, V., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157685 · Cited by 109
Intra-islet insulin permits glucose to directly suppress pancreatic A cell function.
Greenbaum, C. J., Havel, P. J., Taborsky, G. J., & Klaff, L. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115375 · Cited by 106
Arafat, A. M., Kaczmarek, P., Skrzypski, M., Pruszyńska‐Oszmałek, E., Kolodziejski, P. A., Szczepankiewicz, D., Sassek, M., Wojciechowicz, T., Wiedenmann, B., Pfeiffer, A. F. H., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2803-y · Cited by 97
The Role of GLP-1 in the Life and Death of Pancreatic Beta Cells
Perfetti, R., & Hui, H. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826167 · Cited by 86 · cited 5×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialBurmeister, M. A., Ferre, T., Ayala, J. E., King, E. M., Holt, R. M., & Ayala, J. E. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00409.2011 · Cited by 81 · cited 1×
“Other studies have demonstrated that activation of the GLP-1R in the central nervous system reduces hepatic glucose output (43).”
BackgroundOmar, B. A., Andersen, B., Hald, J., Raun, K., Nishimura, E., & Ahrén, B. (2014) · Diabetes · doi:10.2337/db13-0710 · Cited by 76 · cited 12×
“In an OGTT 1 week after STZ administration, Gcgr2/2 mice continued to show rapid glucose clearance; however, STZ-treated DKO animals displayed marked glucose intolerance (area under the curve [AUC] = 1,571 mg/dL/min) compared with Gcgr2/2 mice (AUC = 647 mg/dL/min) and compared with their preSTZ treatment profile (AUC…”
BackgroundMethodResultInfluentialGhazi, T., Rink, L., Sherr, J. L., & Herold, K. C. (2014) · Diabetes Care · doi:10.2337/dc13-1169 · Cited by 54
Effects of Glucagon-like Peptide 1 on the Hepatic Glucose Metabolism
D'Alessio, D., Vahl, T., & Prigeon, R. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826172 · Cited by 52
Dardevet, D., Moore, M. C., DiCostanzo, C. A., Farmer, B., Neal, D. W., Snead, W., Lautz, M., & Cherrington, A. D. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00121.2005 · Cited by 48
Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect
Dhanesha, N., Joharapurkar, A. A., Shah, G. B., Dhote, V. V., Kshirsagar, S. G., Bahekar, R. H., & Jain, M. R. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70740-5 · Cited by 37 · cited 4×
“Use of the Gcgr, Glp-1r, and Gcgr:Glp-1r genetic models here builds on previous work in Gcgr mice showing that administration of the GLP-1R peptide antagonist, exendin-4(9-39), worsens glucose tolerance in these animals (19).”
BackgroundMethodResultInfluentialRondas, D., Bugliani, M., D’Hertog, W., Lage, K., Masini, M., Waelkens, E., Marchetti, P., Mathieu, C., & Overbergh, L. (2013) · Journal of Proteome Research · doi:10.1021/pr400527q · Cited by 32
Jun, L. S., Showalter, A. D., Ali, N., Dai, F., Ma, W., Coskun, T., Ficorilli, J. V., Wheeler, M. B., Michael, M. D., & Sloop, K. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093746 · Cited by 32 · cited 9×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialSelf-citation
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Further, glucagon receptor KO mice also have compensatory increases in a-cell GLP-1, and GLP-1 receptor (GLP-1R) signaling has been reported to contribute to the preserved glucose responses after streptozotocin administration [166,167].”
BackgroundGlucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Self-citationIslet α cells and glucagon--critical regulators of energy homeostasis
Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266
The glucoregulatory actions of leptin
D'souza, A. M., Neumann, U. H., Glavas, M. M., & Kieffer, T. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.011 · Cited by 216
Metadata
- Authors
- Jun, L. S., Millican, R. L., Hawkins, E. D., Konkol, D. L., Showalter, A. D., Christe, M. E., Michael, M. D., & Sloop, K. W.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Sloop, Kyle W.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-10-06
- Volume
- 64
- Issue
- 3
- Pages
- 819-827
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2106971468
- Cited by
- 60
- References
- 47
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 6 · 2023: 4 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 5 · 2017: 7 · 2016: 8 · 2015: 8 · 2014: 1
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor, glucagon receptor, endogenous glucose production, glucose homeostasis, insulin deficiency, type 1 diabetes, glucagon, glucose tolerance, hyperglycemia, ketoacidosis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Glucagon, Glucose, Immunohistochemistry, Insulin, Streptozocin, Receptors, Glucagon, Mice, Knockout, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.